A
Agilent Technologies
Is A Halal?
Analytical laboratory tools are generally permissible, subject to end-use review.
What You Should Know
Agilent's April 30, 2026 filing shows debt/assets of 25.68%, liquidity/assets of 13.83%, receivables plus cash/assets of 25.30% and disclosed interest income/revenue of 0.71%. Its life-sciences, diagnostics, CrossLab and applied-markets instruments are generally permissible, while pharmaceutical, chemical, environmental, government and customer end uses are not allocated into a universal prohibited-revenue numerator.
⚠️ Concerns
- •No reproducible prohibited-activity revenue allocation is disclosed by customer or end use
- •Applied Markets products can serve chemical, energy, environmental and industrial applications
- •Life-science and diagnostics workflows require product and research-ethics review
- •Financial ratios pass the examined asset-based screens, but business classification remains incomplete
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-04-30; calculated 2026-07-14.
3,355 / 13,065
1,807 / 13,065
3,305 / 13,065
13 / 1,835
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 25.68%, liquidity/assets is 13.83%, receivables plus cash/assets is 25.30% and interest income/revenue is 0.71%, below the examined limits; business classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 25.68%, liquidity/assets is 13.83% and receivables plus cash/assets is 25.30%, below the examined MSCI total-assets limits; activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined ratios pass at debt/assets 25.68% and liquidity/assets 13.83%; activity classification remains incomplete and this is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored and business classification remains incomplete, so market-cap methods are not estimated from a current spot price.
Business-activity disclosure
Agilent supplies analytical instruments, software, services and consumables across life-sciences and diagnostics, CrossLab and applied-markets segments. Laboratory and measurement tools are generally permissible, while clinical, pharmaceutical, chemical, environmental, government and customer end uses require continuing review.
Limitation: The filing does not allocate revenue into a universal prohibited-activity numerator for customer end uses, regulated products, pharmaceutical workflows, government contracts or long-term investments.
Purification
Agilent discloses $13 million of interest income but does not prescribe a scholar-approved purification percentage; the disclosed ratio is evidence for the income screen, not a complete purification prescription.
Inputs, assumptions and primary sources
- Amounts are USD millions from Agilent's April 30, 2026 Form 10-Q and rounded to the nearest million.
- Debt includes $304 million of short-term debt and $3,051 million of long-term debt; operating leases are excluded.
- Cash and cash equivalents are $1,807 million. Long-term investments of $136 million are not added because the filing does not identify them as interest-bearing securities.
- Accounts receivable, net are $1,498 million and second-quarter net revenue is $1,835 million; disclosed interest income is $13 million.
- Agilent's fiscal year ends October 31; April 30, 2026 is the six-month fiscal-period balance-sheet date and second-quarter income statement period.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →